U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033

26 Dec 2024

Share :

Table of Content

1. U.S. Stem Cell Therapy Market Revenue and Trends 2023 to 2033 2. Market Overview  3. Report Highlights of the U.S. Stem Cell Therapy Market  4. Major Trends in the U.S. Stem Cell Therapy Market 5. Country Insights 6. U.S. Stem Cell Therapy Market Coverage 7. Market News 8. U.S. Stem Cell Therapy Market Key Players

U.S. Stem Cell Therapy Market Revenue and Trends 2023 to 2033

The U.S. stem cell therapy market revenue surpassed USD 5.99 billion in 2024 and is predicted to attain around USD 17.70 billion by 2033, growing at a CAGR of 12.79%. The rising prevalence of chronic diseases and innovations in stem cell-based therapies drive the growth of the market. 

Market Overview 

Stem cell therapy is an ideal approach to eliminate generative deficiencies by replacing diseased cells. It replaces tissue or organs damaged by age, disease, or injuries. Stem cells have the ability to regenerate new tissues in the human body and, hence, are mostly used for therapeutic purposes in tissue regeneration and repair.

The U.S. stem cell therapy market has been witnessing rapid growth due to the increasing cases of osteoarthritis and musculoskeletal diseases. Stem cell therapy has the potential to heal wounds and is also under development for treating diseases like rheumatoid arthritis, Crohn's disease, and multiple sclerosis.  In addition, the increasing funding by private and commercial sectors in stem cell therapy and innovations in technologies like 3D printing propel the market for U.S. stem cell therapy. The rising demand for personalized therapies that possess fewer side effects on the patients and the increasing use of CRISPR technology further contribute to market expansion.

Report Highlights of the U.S. Stem Cell Therapy Market 

• By product, the adult stem cells (ASCs) segment led the market in 2023. This is mainly due to their increased use in treating cardiovascular diseases, neurological disorders, and orthopedic injuries. These cells have several benefits, such as being easily available and removing them from tissues like bone marrow or adipose tissue with fewer chances of immunological rejection. Moreover, technological advancements have made it impossible to isolate and culture adult stem cells with improved outcomes.
• By therapy type, the allogenic segment registered dominance in the market in 2023, as it offers several benefits like a short treatment plan and availability of more cells for the treatment at a lower cost. Moreover, allogenic therapy can produce standardized cell products with safe treatment and effective results.
• By technology, the cell production segment led the market in 2023 due to advancements in stem cell production that made it possible to effectively meet the increasing demand for cell-based therapy. Also, regulatory frameworks and collaborations with research centers, universities, and biotech firms boosted cell production. 
• By application, the regenerative medicine segment registered dominance in the market in 2023. The demand for regenerative medicines has increased over the past years due to a significant growth in the prevalence of chronic diseases, which is a major factor bolstering the segmental growth. Regenerative medicine repairs and replaces damaged organs and tissues by utilizing stem cells. It is also beneficial in treating several diseases, such as autoimmune, neurological, orthopedic, and cardiovascular diseases.  
• By end-user, the hospitals segment led the market in 2023 due to the easy availability of novel therapeutics with advanced medical technology and facilities in these settings that offer proper medical treatments with improved outcomes. Also, the increased patient pool in hospitals augmented segmental growth.

Major Trends in the U.S. Stem Cell Therapy Market

• Rising Research and Development: With the rising prevalence of various diseases, there is a need to discover new sources of stem cells to accelerate the production of stem cell therapies. Thus, researchers are making efforts to identify and explore new stem cell types with improved efficacy and patient outcomes, which in turn drive market growth.
• Rising Cases of Chronic and Degenerative Diseases: Increasing cases of chronic diseases, such as diabetes, cancer, and cardiovascular diseases, and degenerative diseases, such as osteoporosis, osteoarthritis, and Alzheimer's disease, are expected to propel the growth of the market. There is a lack of availability of therapeutics for several chronic and degenerative diseases, wherein stem cell therapy proves to be an ideal option for patients who want to address the underlying cause of these diseases. Moreover, stem cell therapy helps regenerate or replace disease cells, which further promotes healing. 
• Technological Advancements: Advancements in delivery technologies help stem cells to properly target and release under controlled conditions by improving the therapeutic potential and reducing the side effects. Moreover, innovations in stem cell manufacturing technologies create immense opportunities in the market.

Country Insights

The presence of well-established healthcare and research infrastructure and high investments in clinical research for developing innovative stem cell-based therapies contribute to the growth of the U.S. stem cell therapy market. Researchers are exploring cell-based therapies to treat several conditions like diabetes, stroke, Alzheimer's disease, and cardiac disorders. Also, the rising approvals for stem cell therapies are propelling the market. The U.S. government is also investing in research and development of stem cell therapies to examine the effectiveness of these therapies in treating various ailments.

• For instance, the Board of the California Institute for Regenerative Medicine approved investing nearly US$ 89 million in projects from its clinical and translation programs. Nearly US$ 39 million supported four projects in the agency's clinical program, which provides funding for eligible stem cell and gene therapy-based projects.

U.S. Stem Cell Therapy Market Coverage

Market News

• In November 2024, the Global Institute of Stem Cell Therapy and Research, Inc. (GIOSTAR) announced the FDA clearance of IND for starting phase-2 clinical trials for developing specific stem cell therapy for type 2 diabetes.
• In October 2024, the University of Southern California (USC) collaborated with StemCardia to develop cellular and genetic therapy to address heart failure. The primary goal of the partnership is to develop new cell replacement therapies, including induced pluripotent stem cells, to regenerate heart muscles and create new gene therapies to strengthen heart muscle contraction.

U.S. Stem Cell Therapy Market Key Players

• Caladrius
• CELGENE CORPORATION
• Opexa Therapeutics, Inc.
• Seneca Biopharmaceuticals, Inc.

Market Segmentation

By Product

• Adult Stem Cells (ASCs)
  • Hematopoietic
  • Mesenchymal
  • Neural
  • Epithelial/Skin
  • Others
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic Like Stem Cells

By Therapy Type

• Autologous
• Allogenic

By Application

• Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Hematology
  • Cardiovascular and Myocardial Infraction
  • Injuries
  • Diabetes
  • Liver Disorder
  • Incontinence
  • Others
• Drug Discovery and Development

By Technology

• Cell Acquisition
  • Bone Marrow Harvest
  • Umbilical Blood Cord
  • Apheresis
• Cell Production
  • Therapeutic Cloning
  • In-vitro Fertilization
  • Cell Culture
  • Isolation
• Cryopreservation
• Expansion and Sub-Culture

By End User

• Hospitals
• Research Institutes
• Surgical Institutes
• Orders

Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/3850

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344